Parkinson's Disease: From Pathogenesis to Pharmacogenomics

Area of Science:

• Neuroscience
• Pharmacology
• Genetics

Background:

• Parkinson's disease (PD) is the second leading age-related neurodegenerative disorder, characterized by motor symptoms like rigidity and tremor.
• Neurodegeneration in PD often precedes motor symptoms by decades, influenced by environmental and genetic factors.
• Neuropathology involves dopaminergic neuron loss in the substantia nigra, impacting CNS and peripheral tissues.

Purpose of the Study:

• To review current understanding of Parkinson's disease pathogenesis and treatment.
• To highlight limitations of conventional PD therapies, such as the wearing-off phenomenon.
• To emphasize the need for novel therapeutic strategies focusing on neuroprotection and personalized medicine.

Main Methods:

• Review of scientific literature on Parkinson's disease.
• Analysis of pathogenic mechanisms including protein conformational changes, ubiquitin-proteasome system, mitochondrial dysfunction, and oxidative stress.
• Examination of current and novel pharmacological treatments for PD.

Main Results:

• Conventional PD treatments (levodopa, dopamine agonists, MAO inhibitors, COMT inhibitors) manage symptoms but cause complications.
• Novel drug development focuses on dopaminergic neuroprotection and enhanced neurotransmission.
• Pharmacogenetic approaches are crucial for tailoring treatments to individual patient profiles.

Conclusions:

• Future PD treatments must integrate neuroprotection with symptomatic relief.
• Personalized medicine, guided by pharmacogenetics, is essential for optimizing therapeutic outcomes in Parkinson's disease.
• Addressing underlying pathogenic mechanisms is key to developing more effective PD therapies.